FDA warns against aliskiren combos for diabetes and kidney patients

04/22/2012 | MedPage Today (free registration)

Combining aliskiren with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers might lead to renal impairment, hypotension and hyperkalemia in patients with diabetes, the FDA said. The agency also advised patients with renal impairment to avoid such a combination.

View Full Article in:

MedPage Today (free registration)

Published in Briefs: